FEops HEARTguide authorized by FDA for unprecedented LAAo planning capabilities
Ghent, Belgium: 14 October 2021 – FEops today announced that it received De Novo authorization from the U.S. Food and Drug Administration (FDA) for FEops HEARTguide™ pre-operative planning of left atrial appendage occlusion with the Boston Scientific WATCHMAN™ device*. FEops HEARTguide™ will enable physicians to virtually model clinical scenarios with different implant positions and sizes of the WATCHMAN™ device helping the heart team to select the optimal size and position for every individual patient.
“The preoperative insight provided by FEops HEARTguide™ is powerful and can help me to opti-mize decision making for selecting optimal device size and position”, said Dr Jacqueline Saw, Van-couver General Hospital, Canada. “FEops HEARTguide™ is an intuitive platform I can use to discuss cases with the entire heart team to streamline my pre-op planning workflow.”
More info on FEops‘s website.